Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.

Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy. We now formally show that CRC cells build a barrier to chemotherapeutics by increasing mucins' secretion. We show that low levels of KChIP3, a negative regulator of mucin secretion (Cantero-Recasens et al., 2018), is a risk factor for CRC patients' relapse in a subset of untreated tumours. Our results also reveal that cells depleted of KChIP3 are four times more resistant (measured as cell viability and DNA damage) to chemotherapeutics 5-fluorouracil + irinotecan (5-FU+iri.) compared to control cells, whereas KChIP3-overexpressing cells are 10 times more sensitive to killing by chemotherapeutics. A similar increase in tumour cell death is observed upon chemical inhibition of mucin secretion by the sodium/calcium exchanger (NCX) blockers (Mitrovic et al., 2013). Finally, sensitivity of CRC patient-derived organoids to 5-FU+iri. increases 40-fold upon mucin secretion inhibition. Reducing mucin secretion thus provides a means to control chemoresistance of mucinous CRC cells and other mucinous tumours. © 2022, Cantero-Recasens et al.

Citation

Gerard Cantero-Recasens, Josune Alonso-Marañón, Teresa Lobo-Jarne, Marta Garrido, Mar Iglesias, Lluis Espinosa, Vivek Malhotra. Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. eLife. 2022 Feb 08;11

Mesh Tags

Substances

PMID: 35131032

search → result